The European Medicines Agency has updated the Q&A document on how companies should go about identifying, redacting, anonymizing and submitting clinical trial documents ahead of the phased re-start of its landmark transparency policy in September.
The Q&As have been revised to clarify the scope of the Clinical Data Publication (CDP) policy, and address procedural changes...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?